Company intelligence / Profile preview

Samyang Holdings

Ownership: Private
Employees: ~380
Development stage: Commercial

Overview

Samyang Holdings’ biopharmaceutical division has commercialized polymer-based biodegradable sutures globally and developed cytotoxic anticancer drugs for solid and blood cancers. The company continues to invest in R&D for innovative drug delivery technologies and genetic therapies. It operates manufacturing plants in Korea and Hungary with a US subsidiary focused on open innovation. Clinical results are not detailed publicly but products are available commercially.

Therapeutic areas: OncologyOther
Modalities: Small molecules (anticancer drugs)Gene therapeuticsMedical devices (biodegradable polymers/sutures)Proprietary drug delivery systems
Industry: Biotech

Beyond the preview

Go deeper on Samyang Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Samyang Holdings.

Explore the full profile